NASDAQ:BNGO - Bionano Genomics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.06
  • Forecasted Upside: 68.55 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.97
▼ -0.19 (-3.08%)

This chart shows the closing price for BNGO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bionano Genomics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BNGO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BNGO

Analyst Price Target is $10.06
▲ +68.55% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Bionano Genomics in the last 3 months. The average price target is $10.06, with a high forecast of $15.00 and a low forecast of $1.25. The average price target represents a 68.55% upside from the last price of $5.97.

This chart shows the closing price for BNGO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Bionano Genomics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/16/2021BTIG ResearchInitiated CoverageBuy$10.00High
3/24/2021OppenheimerReiterated RatingBuyHigh
2/8/2021OppenheimerBoost Price Target$1.50 ➝ $15.00Low
1/22/2021Maxim GroupBoost Price Target$2.00 ➝ $14.00High
12/4/2020Roth CapitalDowngradeBuy ➝ NeutralLow
9/24/2020LADENBURG THALM/SH SHInitiated CoverageBuy$1.25Medium
8/24/2020OppenheimerReiterated RatingBuyHigh
8/17/2020Maxim GroupInitiated CoverageBuy$2.00Medium
7/24/2020Maxim GroupReiterated RatingBuy$2.00High
7/17/2020Maxim GroupReiterated RatingBuy$2.00High
7/10/2020Maxim GroupInitiated CoverageBuy$2.00High
6/11/2020OppenheimerReiterated RatingBuy$1.50Medium
6/4/2020Roth CapitalReiterated RatingBuy$1.00High
4/19/2020OppenheimerInitiated CoverageOutperform$1.50Medium
4/8/2020OppenheimerInitiated CoverageOutperform$1.50High
4/1/2020Roth CapitalReiterated RatingBuyLow
4/1/2020Maxim GroupReiterated RatingBuy$3.00High
3/11/2020Maxim GroupReiterated RatingBuy$3.00High
12/6/2019Maxim GroupReiterated RatingBuy$3.00High
11/8/2019Maxim GroupReiterated RatingBuy$3.00Low
8/9/2019Maxim GroupReiterated RatingBuy$7.00Medium
7/31/2019Maxim GroupSet Price TargetBuy$7.00N/A
6/20/2019Maxim GroupReiterated RatingBuy$11.00Low
5/10/2019Maxim GroupReiterated RatingBuyHigh
4/1/2019Maxim GroupReiterated RatingBuy$11.00Low
3/18/2019Maxim GroupReiterated RatingBuyLow
3/6/2019Maxim GroupUpgradeBuy$11.00High
2/5/2019Roth CapitalReiterated RatingBuyLow
9/26/2018Roth CapitalInitiated CoverageBuy$12.00Medium
9/25/2018Maxim GroupInitiated CoverageBuyHigh
(Data available from 7/25/2016 forward)
Bionano Genomics logo
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $5.97
Low: $5.88
High: $6.17

50 Day Range

MA: $6.67
Low: $5.44
High: $8.40

52 Week Range

Now: $5.97
Low: $0.47
High: $15.69

Volume

6,537,382 shs

Average Volume

13,983,794 shs

Market Capitalization

$1.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Bionano Genomics?

The following equities research analysts have issued reports on Bionano Genomics in the last year: BTIG Research, LADENBURG THALM/SH SH, Maxim Group, Oppenheimer Holdings Inc., Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for BNGO.

What is the current price target for Bionano Genomics?

4 Wall Street analysts have set twelve-month price targets for Bionano Genomics in the last year. Their average twelve-month price target is $10.06, suggesting a possible upside of 68.6%. Oppenheimer Holdings Inc. has the highest price target set, predicting BNGO will reach $15.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $1.25 for Bionano Genomics in the next year.
View the latest price targets for BNGO.

What is the current consensus analyst rating for Bionano Genomics?

Bionano Genomics currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BNGO will outperform the market and that investors should add to their positions of Bionano Genomics.
View the latest ratings for BNGO.

What other companies compete with Bionano Genomics?

How do I contact Bionano Genomics' investor relations team?

Bionano Genomics' physical mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The company's listed phone number is 858-888-7600 and its investor relations email address is [email protected] The official website for Bionano Genomics is www.bionanogenomics.com.